Furthermore, to examine whether the expression of DAB2IP could predict the ESCC response to CRT and patient clinical outcomes, we evaluated the correlation between DAB2IP expression and patient clinical/prognostic factors. This evidence concerns the gene DAB2IP and esophageal squamous cell carcinoma.